New cost benefit analysis reports NHS chronic wound care costs can be reduced by use of haemoglobin spray
· New report shows Granulox[®] (Mölnlycke), an innovative topical haemoglobin spray, is a cost-effective therapy in chronic wound care management as adjunct to standard care[1] · Granulox pays for itself in eight weeks due to reduced healing time and subsequent reduced usage for consumables[1]. · Granulox was shown to heal 90% of wounds treated after 20 weeks of use[1] · In contrast, over a period of six months, only 48% of chronic wound patients healed with standard care alone[1]12 December 2019, Milton Keynes, UK. A controlled evaluation of 100 UK National Health Service (NHS)